{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon&page=3", "query": { "intervention": "Pegylated Interferon", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 202, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T23:48:47.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01479868", "title": "A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Genotype-1" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Pegylated interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 109, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479868" }, { "nct_id": "NCT02471430", "title": "Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2016-05", "completion_date": "2023-12", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471430" }, { "nct_id": "NCT01074008", "title": "A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2010-03", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074008" }, { "nct_id": "NCT00588146", "title": "Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Liver Disease", "Hypoxemia" ], "interventions": [ { "name": "Pegylated Interferon Alpha2b", "type": "DRUG" }, { "name": "Standard care", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2007-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-02-22", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588146" }, { "nct_id": "NCT00055341", "title": "Treatment of Hepatitis C in Hemophilic Patients With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C", "Hemophilia" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 22, "start_date": "2002-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2008-07-30", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055341" }, { "nct_id": "NCT01332019", "title": "Long-Term Safety and Efficacy Study of Peginterferon Beta-1a", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1077, "start_date": "2011-04", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Lexington, Kentucky • Baltimore, Maryland + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Akron", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332019" }, { "nct_id": "NCT02263079", "title": "A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pediatric Immuno-Tolerant Chronic Hepatitis B" ], "interventions": [ { "name": "Entecavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 62, "start_date": "2014-06-16", "completion_date": "2020-01-29", "has_results": true, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 3, "location_summary": "Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania", "locations": [ { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02263079" }, { "nct_id": "NCT05070364", "title": "Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis Delta Virus" ], "interventions": [ { "name": "Peginterferon Lambda-1a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 150, "start_date": "2021-12-21", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 7, "location_summary": "Los Angeles, California • Redwood City, California • San Francisco, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070364" }, { "nct_id": "NCT02125578", "title": "A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "BIIB017 (PEGylated Interferon Beta-1a)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 69, "start_date": "2008-03", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02125578" }, { "nct_id": "NCT01482767", "title": "Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Pegylated-Interferon Alfa 2b (PEG-IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" }, { "name": "Boceprevir (BOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 262, "start_date": "2012-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-04T23:48:47.384Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482767" } ] }